Improved Efficacy of Cotrimoxazole with Medicinal Synthetic Aluminum-Magnesium Silicate for Effective Treatment of Trypanosomosis

Akpan, Clara Amaka Nkpoikanke *

Department of Veterinary Medicine, College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.

Ezeibe, Maduike Chiehiura Onwubuko

Department of Veterinary Medicine, College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.

Sanda, Mary Ekundayo

Department of Veterinary Medicine, College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.

Okey, Stephen Nnaemeka

Department of Veterinary Biochemistry and Animal Production, College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.

Ogbonna, Ijeoma Joy

Department of Veterinary Medicine, College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.

Ezeibe, Favour Ijeoma

Department of Veterinary Biochemistry and Animal Production, College of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Aims: The mechanism of Cotrimoxazole (Sulfamethoxazole and Trimethoprim combination) as an anti-bacterial drug is inhibition of Folic Acid but its anti-trypanocidal efficacy has not been investigated though Trypanosomes also require Folic Acid for replication. Development of resistance by Trypanosomes against drugs, frequent relapse infections and toxicity of most trypanocides demand that the search for new Trypanocidal drugs be continuous. Aluminum magnesium silicate (AMS) and its formulation named Medicinal Synthetic AMS (MSAMS) have been reported to stabilize other medicines. Stabilizing medicines improves the length of time they remain at high bioavailability and when drugs remain at high concentration in plasma for a long time, their efficacies improve. Improving the anti-folic acid efficacy of Cotrimoxazole may deny Trypanosomes Folic Acid to the extent that their replication could be inhibited.

Study Design: Fifteen West African Dwarf (WAD) sheep allotted to 3 groups of 5 animals each were used. One group was infected and treated, the second group was infected and untreated while the third group was uninfected and untreated.

Place and Duration of Study: the study was conducted in the Department of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike/ for a period of 7 months.

Methodology: Five (5) Trypanosoma b. brucei infected sheep (WAD) were treated with Cotrimoxazole MSAMS formulation at dose of 120mg/kg orally for 5 days while another group was left untreated.

Results: Mean parasitaemia of 80.49±7.56 million parasite per ml of blood was recorded just before commencement of the treatment but nine days after treatment with the Cotrimoxazole-MSAMS formulation the parasitaemia of the treated group reduced (P≤ 0.05) from 2.25±1.50 in the control to 0.00± 0.00). Cotrimoxazole-MSAMS terminated parasitaemia in Trypanosoma b. brucei infected WAD sheep 9 days post-treatment. Relapse infection was not observed up to 100 days post-treatment.

Conclusion: MSAMS enhanced the anti-folic acid efficacy of Cotrimoxazole so that it cleared Trypanosome parasitaemia and there was no relapse.

Keywords: Efficacy, cotrimoxazole, medicinal synthetic aluminum magnesium silicate, trypanosomosis, West African Dwarf Sheep


How to Cite

Nkpoikanke, Akpan, Clara Amaka, Ezeibe, Maduike Chiehiura Onwubuko, Sanda, Mary Ekundayo, Okey, Stephen Nnaemeka, Ogbonna, Ijeoma Joy, and Ezeibe, Favour Ijeoma. 2023. “Improved Efficacy of Cotrimoxazole With Medicinal Synthetic Aluminum-Magnesium Silicate for Effective Treatment of Trypanosomosis”. Asian Journal of Research in Animal and Veterinary Sciences 6 (4):472-82. https://doi.org/10.9734/ajravs/2023/v6i4275.

Downloads

Download data is not yet available.

References

Goldberg E, Bishara J. Contemporary unconventional clinical use of co-trimoxazole. Clinical Microbiology and Infection. 2012;18:8–17.

Jiang J, Qin F, Meng S, Nehl EJ, Huang J, Liu Y. et al. Effects of Cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: A retrospective cohort study. Emerging microbes & infections. 2019;8(1):367–376. Available:https://doi.org/10.1080/22221751.2019.1588078

Gutiérrez JMDR, Sancho PS, Diaz HCG, Parra AP, Galcera CV, Domingo DA. et al. Cotrimoxazole: How folate supplementation could affect treatment efficacy. European Journal of Hospital Pharmacy. 2022;29:A170-A171.

World Health Organization. Guidelines on Post-Exposure prophylaxis for HIV and the use of Co-Trimoxazole prophylaxis for HIV-Related Infections among Adults, Adolescents and Children: Recommendations for a Public Health Approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2014. Available:https://www.ncbi.nlm.nih.gov/books/NBK298965/

Hamel MJ, Holtz T, Mkandala C, Kaimila N, Chizani N, Bloland P. et al. Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. The American Journal of Tropical Medicine and Hygiene. 2005;73(3):609–615.

Verdier RI, Fitzgerald DW, Johnson WD, Pape JW.Trimethoprim–sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Annals of Internal Medicine, 2000;132:885–888.

Fehintola FA. Cotrimoxazole, clinical uses and malaria chemotherapy. African Journal of Medicine and Medical Sciences; 2010;39(1):63-68.

Fung KT, Dhillon AP, McLaughlin JE, Lucas SB, Davidson B, Rolles K, et al. Cure of Acanthamoeba cerebral abscess in a liver transplant patient. Liver transplantation: Official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2008;14(3):308–312. Available:https://doi.org/10.1002/lt.21409

Beraud G, Pierre-François S, Foltzer A, Abel S, Liautaud B, Smadja D, Cabié A. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. The American Journal of Tropical Medicine and Hygiene. 2009;80(4):583–587.

Alavi SM, Alavi L. Treatment of toxoplasmic lymphadenitis with co-trimoxazole: double-blind, randomized clinical trial, International Journal of Infectious Diseases. 2010;14(3):e67-e69. ISSN 1201-9712. Available:https://doi.org/10.1016/j.ijid.2009.11.015

Ezeibe MCO, Ezeja MI, Akpan CA, Onyeachonam FIO, Sanda ME, Ogbonna IJ. et al. Antivirt ® {Al4 (Sio4)3 + 3Mg2SiO4 → 2Al2 Mg3 (Sio4)3} Enhances Efficacy of Co-trimoxazole to Terminate Experimental Trypanosome-Infections in Mice. Global Journal of Medical Research: G Veterinary Science and Veterinary Medicine. 2020;20(3)

Anyogu DC, Shoyinka VS, Ihedioha JI. Effects of prolonged treatment with Co-trimoxazole on the Thyroid Gland, Liver, and Epididymal Sperm Reserve in Dogs. Clinical Medicine Insights. Pathology. 2017;10:1179555717742881. Available:https://doi.org/10.1177/1179555717742881

Ovung A, Bhattacharyya J Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions. Biophysical Reviews. 2021; 13:(2):259–272. Available:https://doi.org/10.1007/s12551-021-00795-9

Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-Sulfamethoxazole Revisited. Archives of Internal Medicine; 2003;163(4):402–410. DOI:10.1001/archinte.163.4.402

Queener SF, Cody PVJ, Torkelson P, Gangjee A. Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of Pneumocystis jirovecii. Antimicrobial Agents and Chemotherapy. 2013;57(10):4990–4998. DOI: 10.1128/AAC.01161-13

Kaartinen L, Gips M, Laurila T, Härtel H, Soback S, Pyorala S. Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. Veterinary Research. 2000;31(5):517-526. ff10.1051/vetres:2000137

Ezeibe MCO, Okafor UC, Okoroafor ON, Eze JI, Ngene AA, Animoke PC. et al. Effect of Aluminum Magnesium Silicate on anticoccidial activity of sulphadimidine. Tropical Veterinarian. 2011;29:41-44.

Lee S, Hayashi H, Maeda M, Matsuzaki H, Kumagai-Tkei N, Immunostimulation by Silica particles and the development of autoimmune dysregultion. Immune Response Activation, Guy Huynh Thien Duc, IntechOpen; 2014.

Doi: 10.57772/57544.

Brent W, Gunderson GH, Ross KHI, John CR. What Do We Really Know about Antibiotics Pharmacodynamics? Pharmacotherapy.2001;21:28-31. Available:https://doi.org/10.1592/phco.21.18.302S.33905.

Murray KR. Harpers Biochemistry., McGraw Hill, New York; 2000.

Ezeibe MCO. The synthetic aluminum magnesium silicate. Great AP Express Pub. Ltd. Nsukka, Nigeria; 2009.

Vanderbilt Report. Technical Information: VEEGUM – The versatile ingredient for Pharmaceutical Formulations. R.T. Vanderbilt Company, , Bulletin No. 91R. R.T. Vanderbilt Company Inc., Norwalk; 2012

Elmore AR. Final report on the safety asseessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller’s earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. International Journal of Toxicology. 2003;22-Suppl(1):37-102.

Ezeibe MCO. Admacine. Federal republic of Nigeria. Patents and Design Act Cap.344. LFN. 1990. No. RP 1644; 2006.

Galindo LA, Cereso P. Compositional technical and safety specification of clay to be used as pharmaceutical and cosmetic products. Journal of Renal Nutrition. 2006;2:38-40.

Ezeibe MCO, Elendu-Eleke NP, Okoroafor ON, Ngene AA. Adjuvant effect of a synthetic Aluminum-Magnesium Silicate on chloroquine phosphate, against Plasmodium berghei. Naure. Precedings; 2012 Available:http.10101/npre20126749.1.

Meng HS, Yang Z, Li T, Xia J, Chen Z, Ji H, et al. Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent Macropinocytosis mechanism. ACS Nano. 2011;(6):4434-4447.

Ezeibe MCO. Medicinal synthetic Aluminum-Magnesium silicate (Nanoparticles)—Antiviral agent and adjuvant to chemotherapeutics,. Federal Republic of Nigeria Patents and Designs Ref No. NG/P/2012/639; 2012.

Muhanguzi D, Okello WO, Kabasa JD, Waiswa C, Welburn SC, Shaw APM. Cost analysis of options for management of African animal Trypanosomiasis using interventions targeted at cattle in Tororo district; South-eastern Uganda. Parasit. Vectors. 2015;8:387.

Samdi SM, Abenga JN. Attahir A, Haruna MK, Wayo BM, Fajinmi AO. et al. Impact of trypanosomosis on foodsecurity. Security in Nigeria: A review. Int. J. Anim. Vet. Adv. 2010; 2(2):47-50.

Hoet S, Pieters L, Muccioli GG, Habib-Jiwan J, Opperdoes FR, Quentin-Leclercq J, Antitrypanosomal activity of triterpenoids and sterols from the leaves of Strychnos spinosa and related compounds. Journal of Natural Products. 2007;70:1360-1363.

Bizimana N, Tietjen U, Zessin KH, Diallo D, Djibril D, Melzig MF. et al. Evaluation of medicinal plants from Mali for their In vitro and In vivo trypanocidal activity. Journal of Ethnopharmacology. 2006;103:350-356.

Institute for International Cooperation in Animal Biologics (IICAB); 2009. Available:http://www.cfsph.iastate.edu/Factsheets/pdfs/trypanosomiasis_african.pdf.

Auty H, Torr SJ, Michoel T, Jayaraman S, Morrison LJ. Cattle trypanosomosis: the diversity of trypanosomes and implications for disease epidemiology and control. Revue scientifique et technique (International Office of Epizootics). 2015;34(2):587-598.

Giordani F, Morrison LJ, Rowan TG, DE Koning HP, Barrett MP. The animal trypanosomiases and their chemotherapy: A review. Parasitology. 2016;143(14):1862–1889. Available:https://doi.org/10.1017/S0031182016001268

Moloo SK, Kabata JM, Gitire NM. Study on the mechanical transmission by tsetse fly Glossina morsitans centralis of Trypanosoma vivax, T. congolense or T. brucei brucei to goats. Acta tropica. 2000;74(1):105-108.

Ahmed SK, Rahman AH, Hassan MA, Salih EM, Paone M, Cecchi G. An atlas of tsetse and bovine trypanosomosis in Sudan. Parasites & vectors. 2016;9(1):1-8.

Desquesnes M, Dia MI. Trypanosoma vivax. Mechanical transmission in cattle by one of the most common African tabanids – Atylotus agrestic. Veterinary Parasitology. 2003;119:9-19.

Desquesnes M, Biteau-Coroller F, Bouyer J, Dia ML, Foil L. Development of a mathematical model for mechanical transmission of trypanosomes and other pathogens of cattle transmitted by tabanids. International Journal for Parasitology. 2009;39:333–346.

Onditi SJ, Silayo RS, Kimera SI, Kimbita EN, Mbilu TJNK. Preliminary studies on prevalence and importance of goat trypanosomosis in selected farms in Morogoro District,Tanzania. Livestock Research for Rural Development. 2007;19:65]

Taylor K, Authie E. Pathogenesis of Animal trypanosomosis. In: The Trypanosomiasis. Edited by: Maudlin, I.; Holmes, P.H. and Mills, M.A. CAB International. UK. 2004;331-353.

Spickler AR. African Animal Trypanosomiasis; 2018. Available:http://www.cfsph.iastate.edu/ DiseaseInfo/factsheets.php. 2018.

Sulaiman FA, Adeyemi OS. Changes in haematological indices and protein concentrations in Trypanosoma brucei infected rats treated with homidium chloride and diminazene aceturate. Excli Journal. 2010;9:39–45.

Sivajothi S, Rayulu VC, Sudhakara RB. Haematological and biochemical changes in experimental Trypanosoma evansi infection in rabbits. Journal of parasitic diseases: official organ of the Indian Society for Parasitology. 2015;39(2):216–220. Available:https://doi.org/10.1007/s12639-013-0321-6

Hutchinson OC, Picozzi K, Jones NG, Mott H, Sharma R, Welburn SC. et al. Variant Surface Glycoprotein gene repertoires in Trypanosoma brucei have diverged to become strain-specific. BMC Genomics. 2007;8:234.

Croos GAM. Antigenic variation in African Trypanosomes and malaria. In: Marr JJ, Nilsen TW, Komuniecky RW. Molecular medical parasitology. San Diego: Academic Press. 2003;82-110.

Frevert U, Movila A, Nikolskaia OV, Raper J, Mackey ZB, Abdulla M. et al. Early invasion of brain parenchyma by African trypanosomes. PloS One. 2012;7(8):e43913. Available:https://doi.org/10.1371/journal.pone.0043913

Horn D. Antigenic variation in African trypanosomes. Molecular and Biochemical Parasitology. 2014;195:123–129.

Barret MP, Boykin DW, Brun R, Tidwell RR. Human African Trypanosomiasis: Pharmacological re-engagement with a neglected disease. British Journal of Pharmacology. 2007;152:1155-1171.

de Koning HP. Transporters in African trypanosomes: Role in drug action and resistance. International Journal for Parasitology. 2001;31(5-6):512–522. Available:https://doi.org/10.1016/s0020-7519(01)00167-9

Holmes PH, Eisler MC, Geerts S. Current chemotherapy of animal trypanosomiasis. In: Ian Maudlin, Peter H. Holmes and Michael A. Miles (eds.). The Trypanosomiasis. CABI International. Wallingford, UK. 2004;431-444.

Cattand PD, Phillipe MG, Guzman J, Janin AK, Medici A, Musgrove P. et al. Tropical diseases lacking adequate control, measures: dengue, leishmaniasis and African trypanosomiasis. Disease Control Priorities in Developing Countries; 2005. Available:http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=dcp2∂=A3138

Kazibwe AJ, Nerima B, de Koning HP, Mäser P, Barrett MP, Matovu E. Genotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawal. PLoS Negl. Trop. Dis. 2009;3:e523. DOI: 10.1371/journal.pntd.0000523

Venturelli A, Tagliazucchi L, Lima C, Venuti F, Malpezzi G, Magoulas GE, et al. Current Treatments to Control African Trypanosomiasis and One Health Perspective. Microorganisms. 2022;10(7):1298. Available:https://doi.org/10.3390/microorganisms10071298

Kasozi KI, MacLeod ET, Ntulume I, Welburn SC. An update on african trypanocide pharmaceutics and resistance. Frontiers in Veterinary Science. 2022;9:828111. Available:https://doi.org/10.3389/fvets.2022.828111

Van den Bossche P, Chigoma D, Shumba W. The decline of anti-trypanosomal antibody levels in cattle after treatment with trypanocidal drugs and in the absence of tsetse challenge. Acta Trop. 2000;77:263-270.

Delespaux V, Dinka H, Masumu J, Van den Bossche P, Geerts S. Five-fold increase in Trypanosoma congolense isolates resistant to diminazene aceturate over a seven-year period in Eastern Zambia. Drug Resistance Updates. 2008;11:205–209.

Bala AY, Adamu T, Abubakar U, Ladan MJ. Inhibition of brucei brucei by extract from Waltheria indica L. (sleepy morning). Research. Journal of. Parasitolology; 2010.

Faremi AY, Ekanem JT. Haematological parameters and enzyme studies in Trypanosoma brucei-infected rats reared on Nigella sativa oil-based diet. Asian Journal of Biochemistry. 2011;6:90-97.

Nagle AS, Khare S, Kumar AB, Supek F, Buchynskyy A, Mathison CJN. et al. Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chemical Reviews. 2014;114(22):11305–11347.

Fioramonti J Bueno L. Hormonal control of gut motility in ruminants and non- ruminants and its nutritional implications. Nutrition Research Reviews. 1988;1:169-188.

Chakwenya J, Lakritz J, Tyler J, Fales WH, James-Kracke M., Smith K.et al. Pharmacokinetics and bioavailability of trimethoprim-sulfamethoxazole in alpacas. Journal of Veterinary Pharmacology and Therapeutics. 2002;25:1–7.

Office International des Epizooties. (OIE). Compendium of diagnostic protocols of the OIE Reference Laboratory for Animal Trypanosomoses of African Origin; 2017.

Murray M, Murray PK, McIntyre WIM. An improved parasitological technique for the diagnosis of African trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1977;71(4):325-326.

Herbert WJ, Lumsden WHR. Trypanosoma brucei; A rapid matching method for estimating the host’s parasitaemia. Experimental Parasitology. 1976;40:427-431.

Duncan OD. Path analysis: sociological examples. American Journal of Sociology. 1966;72: 1-16.

Akpan CA, Nweze NE, Chukwu CC. Effects of Trypanosoma brucei infection and treatment on haematoserological response of West African Dwarf sheep to Brucella abortus vaccine. Comparative Clinical Pathology; 2017 ISSN 1618-5641. 26(5).

Mohammed B, Sani A, Najume DI, Alao L, Akpofure NE. Effect of immunomodulation with levamisol on the course and pathogenesis of acute experimental Trypanosoma congolense infection in sheep. African Journal of Biotechnology. 2009;8(5):827-834.

Wada YA, Okubanjo OO, Rekwot PI, Mohammed B, Oniye SJ. Patency and Clinico-Haematological Pathologies Sequel to Trypanosoma brucei and Trypanosoma evansi Induced Infections in Yankasa Sheep. Nigerian Veterinary Journal. ISSN 0331-3026. 2020;41(2):125 – 143

Dagnachew S, Terefe G, Abebe G, Barry D, McCulloch R, Goddeeris, B. In vivo experimental drug resistance study in Trypanosoma vivax isolates from tsetse infested and non-tsetse infested areas of Northwest Ethiopia. Acta tropica. 2015;146:95–100. Available:https://doi.org/10.1016/j.actatropica.2015.03.014

Elshafie EI, Sani RA, Sharma R, Abubakar IA. Clinical and Haematological Profiles of Malaysian Ponies Experimentally Infected with a Field Strain of Trypanosoma evansi. The Open Parasitology Journal. 2018;6:7-16. DOI: 10.2174/1874421401806010007.

Akpan CAN, Ezeja MI, Ezeibe MCO. Prevalence of trypanosomosis in large and small ruminants in Abia State and Rivers State, Nigeria. Journal of Sustainable Veterinary and Allied Sciences. 2021;1(2):173-177.e-ISSN: 2811-1346.